Sugi Predict

Sugi Predict / Compounds / SCHEMBL19948718

SCHEMBL19948718

SCHEMBL19948718

CN1CCN(c2ccc(-c3nn(COCC[Si](C)(C)C)c4cnc(Cl)nc34)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 2/20 0.40
▸ AURKA O14965 1/20 0.40
▸ MET P08581 1/20 0.40
▸ KIT P10721 1/20 0.40
▸ SRC P12931 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ AXL P30530 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ TYRO3 Q06418 1/20 0.40
▸ DDR1 Q08345 1/20 0.40
▸ MERTK Q12866 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ ALK Q9UM73 1/20 0.40
▸ DGAT1 O75907 1/20 0.37
▸ TLR9 Q9NR96 6/20 0.36
▸ MAP4K1 Q92918 3/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19967588 0.88 RET (0.39) RETAURKAMETKITSRC
SCHEMBL19949945 0.87 RET (0.37) RETAURKAMETKITSRC
SCHEMBL29486796 0.85 ALOX5 (0.41) METALKALDH1A1SMN1; SMN2
SCHEMBL24979363 0.85 ALOX5 (0.41) METALKALDH1A1SMN1; SMN2
SCHEMBL21989871 0.84 TLR9 (0.33) METTLR9CYP1A2CYP3A4HSD17B10
SCHEMBL19949143 0.83 DGAT1 (0.33) DGAT1CASP1CASP7HSD17B10
SCHEMBL19950416 0.83 ALK (0.41) RETAURKAMETKITSRC
SCHEMBL30070358 0.83 ALK (0.41) RETAURKAMETKITSRC
SCHEMBL24979382 0.82 SMN1; SMN2 (0.37) RETKITSRCPDGFRAKDR
SCHEMBL19950721 0.82 ALK (0.44) RETAURKAMETKITSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2025-10-14 — — US disclosed
EP-3856348-B1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS INCYTE CORP (US) 2024-01-03 — — EP disclosed
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2023-01-03 — — US disclosed
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2023-01-03 — — US disclosed
US-20220017521-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-01-20 — — US disclosed
US-20220017521-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-01-20 — — US disclosed
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-02 — — US disclosed
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-02 — — US disclosed
US-11111247-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2021-09-07 — — US disclosed
US-11111247-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2021-09-07 — — US disclosed
US-11014929-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2021-05-25 — — US disclosed
US-20200172545-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-06-04 — — US disclosed
US-20200172545-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-06-04 — — US disclosed
WO-2020068729-A1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS INCYTE CORPORATION (US) 2020-04-02 — — WO disclosed
WO-2020068729-A1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS INCYTE CORPORATION (US) 2020-04-02 — — WO disclosed
US-20200095250-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-26 — — US disclosed
US-20200095250-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-26 — — US disclosed
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172545-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, MAPKAPK5 RET 2718/4885AURKA 1186/4885MET 3795/4885
US-20200095250-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF ALK, FGFR1, FGFR2 RET 8/4885AURKA 457/4885MET 64/4885
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof ALK, FGFR1, FGFR2 RET 8/4885AURKA 457/4885MET 64/4885
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 RET 2922/4885AURKA 1473/4885MET 3420/4885
US-11014929-B2 Pyrazolopyrimidine compounds and uses thereof PDXK, PCK1, MAPKAPK5 RET 2718/4885AURKA 1186/4885MET 3795/4885
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof PDXK, PCK1, PDK2 RET 2922/4885AURKA 1473/4885MET 3420/4885
US-20220017521-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF ALK, FGFR1, FGFR2 RET 8/4885AURKA 457/4885MET 64/4885
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 RET 2922/4885AURKA 1473/4885MET 3420/4885
US-11111247-B2 Pyrazolopyrimidine compounds and uses thereof ALK, FGFR1, FGFR2 RET 8/4885AURKA 457/4885MET 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.